[1] Kwon T, Lamster IB, Levin L. Current concepts in the management of periodontitis. Int Dent J, 2021; 71, 462−76. doi:  10.1111/idj.12630
[2] Kocher T, König J, Borgnakke WS, et al. Periodontal complications of hyperglycemia/diabetes mellitus: epidemiologic complexity and clinical challenge. Periodontology, 2018; 78, 59−97. doi:  10.1111/prd.12235
[3] Sima C, Viniegra A, Glogauer M. Macrophage immunomodulation in chronic osteolytic diseases-the case of periodontitis. J Leukoc Biol, 2019; 105, 473−87. doi:  10.1002/JLB.1RU0818-310R
[4] Ti DD, Hao HJ, Tong C, et al. LPS-preconditioned mesenchymal stromal cells modify macrophage polarization for resolution of chronic inflammation via exosome-shuttled let-7b. J Transl Med, 2015; 13, 308. doi:  10.1186/s12967-015-0642-6
[5] Wang H, Feng C, Wang M, et al. Circular RNAs: diversity of functions and a regulatory nova in oral medicine: a pilot review. Cell Transplant, 2019; 28, 819−30. doi:  10.1177/0963689719837917
[6] Zhou ZM, Zhu YY, Gao GS, et al. Long noncoding RNA SNHG16 targets miR-146a-5p/CCL5 to regulate LPS-induced WI-38 cell apoptosis and inflammation in acute pneumonia. Life Sci, 2019; 228, 189−97. doi:  10.1016/j.lfs.2019.05.008
[7] Sabbatinelli J, Giuliani A, Matacchione G, et al. Decreased serum levels of the inflammaging marker miR-146a are associated with clinical non-response to tocilizumab in COVID-19 patients. Mech Ageing Dev, 2021; 193, 111413. doi:  10.1016/j.mad.2020.111413
[8] Leal B, Carvalho C, Ferreira AM, et al. Serum levels of miR-146a in patients with psoriasis. Mol Diagn Ther, 2021; 25, 475−85. doi:  10.1007/s40291-021-00531-9
[9] Micó-Martínez P, Almiñana-Pastor PJ, Alpiste-Illueca F, et al. MicroRNAs and periodontal disease: a qualitative systematic review of human studies. J Periodontal Implant Sci, 2021; 51, 386−97. doi:  10.5051/jpis.2007540377
[10] Gita JB, George AV, Pavithra N, et al. Dysregulation of miR-146a by periodontal pathogens: a risk for acute coronary syndrome. J Periodontol, 2019; 90, 756−65. doi:  10.1002/JPER.18-0466